Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation

The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study

Margaret C. Fang, MD, MPH; Daniel E. Singer, MD; Yuchiao Chang, PhD; Elaine M. Hylek, MD, MPH; Lori E. Henault, MPH; Nancy G. Jensvold, MPH; Alan S. Go, MD

Background—Previous studies provide conflicting results about whether women are at higher risk than men for thromboembolism in the setting of atrial fibrillation (AF). We examined data from a large contemporary cohort of AF patients to address this question.

Methods and Results—We prospectively studied 13,559 adults with AF and recorded data on patients’ clinical characteristics and the occurrence of incident hospitalizations for ischemic stroke, peripheral embolism, and major hemorrhagic events through searching validated computerized databases and medical record review. We compared event rates by patient sex using multivariable log-linear regression, adjusting for clinical risk factors for stroke, and stratifying by warfarin use. We identified 394 ischemic stroke and peripheral embolic events during 15,494 person-years of follow-up off warfarin. After multivariable analysis, women had higher annual rates of thromboembolism off warfarin than did men (3.5% versus 1.8%; adjusted rate ratio [RR], 1.6; 95% CI, 1.3 to 1.9). There was no significant difference by sex in 30-day mortality after thromboembolism (23% for both). Warfarin use was associated with significantly lower adjusted thromboembolism rates for both women and men (RR, 0.4; 95% CI, 0.3 to 0.5; and RR, 0.6; 95% CI, 0.5 to 0.8, respectively), with similar annual rates of major hemorrhage (1.0% and 1.1%, respectively).

Conclusions—Women are at higher risk than men for AF-related thromboembolism off warfarin. Warfarin therapy appears to be as effective in women, if not more so, than in men, with similar rates of major hemorrhage. Female sex is an independent risk factor for thromboembolism and should influence the decision to use anticoagulant therapy in persons with AF. (Circulation. 2005;112:1687-1691.)

Key Words: anticoagulants ■ atrial fibrillation ■ risk factors ■ stroke ■ women

Atrial fibrillation is the most common clinically significant cardiac arrhythmia and a major risk factor for ischemic stroke and peripheral embolism.1 Warfarin therapy substantially reduces the risk of atrial fibrillation–related thromboembolism but also increases the risk for hemorrhage.2 Optimal administration of warfarin requires appropriate risk stratification.

Several prominent schemes are available to facilitate identification of patients at high-enough risk of thromboembolism to merit anticoagulant therapy.2-5 These schemes, however, provide conflicting recommendations as to whether women with atrial fibrillation are at higher risk for stroke independently of other known risk factors. The Stroke Prevention in Atrial Fibrillation (SPAF)3 and Framingham risk scores5 consider women to be at higher risk for ischemic stroke, whereas other studies do not (eg, Atrial Fibrillation Investigators [AFI]2 and CHADS2 risk indexes). Notably, the SPAF investigators found only the subset of women >75 years to be at higher risk for stroke.

Variations in the risk assessment for stroke can lead to significant differences in the use of warfarin therapy for atrial fibrillation.6 To test the hypothesis of whether women are at higher risk for atrial fibrillation–related thromboembolism, we analyzed data from the large AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study cohort, comparing rates of ischemic stroke and peripheral embolism between male and female patients not taking anticoagulants while controlling for other known risk factors for thromboembolism.

Methods

ATRIA is a cohort study of 13,559 adults with diagnosed nonvalvular atrial fibrillation who received care within Kaiser Permanente of Northern California, a large integrated healthcare delivery system. Details of the cohort assembly and validation have been described...
Thromboembolic and Hemorrhagic Events
We searched hospitalization and billing claims databases for primary discharge diagnoses of thromboembolic events (ischemic stroke and peripheral embolism) using validated algorithms. All potential events were individually validated through medical records review by 2 members of a 3-physician outcomes committee, with discrepancies resolved by consensus of the 3-member committee, including outside consultant review in selected circumstances. A validated ischemic stroke was defined as the sudden onset of a neurological deficit persisting >24 hours and not explained by other origins. A validated peripheral embolism required confirmation by radiographic imaging, intraoperative examination, or pathological findings and the absence of underlying atherosclerotic disease in the affected artery. We excluded patients who developed events during inpatient hospitalization or from periprocedural complications. Mortality at 30 days after outcome events was based on review of medical records, health plan databases, and California State death files.

Using previously described and validated methods, we identified hemorrhagic events by searching for primary and secondary diagnoses of intracranial hemorrhage and primary diagnoses of extracranial hemorrhage. We excluded intracranial hemorrhages from major trauma. We defined major hemorrhage as fatal, requiring transfusion of ≥2 U packed blood cells, or hemorrhage into a critical anatomic site.

Clinical Characteristics
Data on patient age and sex were obtained from administrative databases. Medical diagnoses related to stroke and hemorrhage risk were obtained by searching hospital discharge and ambulatory visit databases for specific ICD-9-coded diagnoses using previously described and validated methods. Warfarin exposure was determined using a combination of pharmacy, laboratory, and ambulatory visit databases. Anticoagulation intensity was measured using outpatient assessments of the international normalized ratio (INR) obtained from health plan laboratory databases. For patients receiving warfarin, we calculated the proportion of person-time at different INR intervals using an adapted linear interpolation method. If a person was on warfarin by pharmacy records but the interval between INR measurements was >8 weeks, we did not interpolate INR values for this extended period and categorized these INR periods as “not available.” 18% of total person-time fell into this category. Finally, we assessed for longitudinal exposure to oral estrogens (either alone or in combination therapy with progesterone) on the basis of filled prescriptions found in health plan pharmacy databases and a previously validated algorithm.

Statistical Analyses
We compared clinical characteristics of men and women during periods off warfarin using χ² tests and compared thromboembolism rates using log-linear models with generalized estimating equations. Multivariable log-linear regression was then used to adjust for previously identified stroke risk factors: age (as a continuous variable by decades), prior ischemic stroke, hypertension, congestive heart failure, coronary artery disease, diabetes mellitus, and estrogen replacement therapy, with time-dependent covariates as appropriate. We also tested whether an interaction existed between patient sex and age in the rate of thromboembolism off warfarin, first testing whether an interaction existed when age was dichotomized at 75 years (as reported in SPAF) and then with age as a continuous variable. To assess whether the effectiveness of warfarin varied by sex, we tested the interaction term of warfarin and patient sex in models of thromboembolism that included patients both on and off warfarin therapy. We also compared rates of major hemorrhage by sex, adjusting for risk factors for extracranial and intracranial hemorrhage (age, prior gastrointestinal hemorrhage, hematouria, or other prior hemorrhage, cirrhosis, dementia, mechanical fall during a prior hospitalization, prior stroke, hypertension, and anticoagulation intensity) and tested the interaction term for warfarin and patient sex in models predicting hemorrhagic events.

Results
The cohort included 5795 women and 7764 men. Women were generally older and more likely to have a history of stroke or hypertension but were less likely to have diagnosed coronary disease or diabetes mellitus than men (Table 1). Most men and women had CHADS² risk scores between 0 and 2; only a small proportion of the cohort was categorized in the highest-risk group (Table 1). Among women not taking warfarin, the proportion of person-time on oral estrogen therapy was 21.4% compared with 22.5% among women taking warfarin.
TABLE 2. Annual Unadjusted Incidence Rates of Thromboembolism Among Men and Women With Atrial Fibrillation Not Taking Warfarin Stratified by Known Risk Factors for Stroke and CHADS2 Score*

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Annual Thromboembolism Rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥75 y</td>
<td>Women: 5.0 (4.3–5.7) Men: 2.8 (2.3–3.4)</td>
</tr>
<tr>
<td>Prior ischemic stroke</td>
<td>Women: 9.7 (7.0–13.6) Men: 7.3 (5.2–10.3)</td>
</tr>
<tr>
<td>Diagnosed hypertension</td>
<td>Women: 4.0 (3.4–4.7) Men: 2.4 (2.0–3.0)</td>
</tr>
<tr>
<td>Diagnosed congestive heart failure</td>
<td>Women: 5.7 (4.7–6.9) Men: 2.5 (1.9–3.2)</td>
</tr>
<tr>
<td>Diagnosed coronary artery disease</td>
<td>Women: 4.7 (3.8–6.0) Men: 2.4 (1.9–3.1)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Women: 5.0 (3.7–6.6) Men: 3.1 (2.3–4.2)</td>
</tr>
<tr>
<td>CHADS2 score</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Women: 0.6 (0.2–1.2) Men: 0.5 (0.3–0.9)</td>
</tr>
<tr>
<td>1</td>
<td>Women: 1.8 (1.3–2.4) Men: 1.2 (0.9–1.7)</td>
</tr>
<tr>
<td>2</td>
<td>Women: 4.4 (3.6–5.4) Men: 1.9 (1.4–2.6)</td>
</tr>
<tr>
<td>3</td>
<td>Women: 6.1 (4.8–7.8) Men: 3.9 (2.8–5.3)</td>
</tr>
<tr>
<td>4</td>
<td>Women: 9.1 (6.2–13.3) Men: 6.5 (4.2–10.0)</td>
</tr>
<tr>
<td>5</td>
<td>Women: 7.7 (5.6–16.5) Men: 2.6 (1.8–8.1)</td>
</tr>
<tr>
<td>6</td>
<td>Women: 11.4 (2.5–51.9) Men: 16.2 (7.4–35.6)</td>
</tr>
</tbody>
</table>

*CHADS2 score calculated by assigning 2 points to prior stroke or transient ischemic attack and 1 point to any of the following risk factors: congestive heart failure, hypertension, age ≥75 years, and diabetes mellitus.

**TABLE 2. Annual Unadjusted Incidence Rates of Thromboembolism Among Men and Women With Atrial Fibrillation Not Taking Warfarin Stratified by Known Risk Factors for Stroke and CHADS2 Score**

**Effect of Warfarin Therapy in Women Compared With Men**

The distribution of INR intensities was similar between men and women. In men taking warfarin, 26.8% of the person-time was spent at INR levels <2.0 and 62.7% between 2.0 and 3.0; in women, the proportions were 27.9% and 61.3% (These proportions were calculated excluding the 18% of total person-time for which INR was not available).

Among warfarin users, there were 204 thromboembolic and 167 major hemorrhagic events over ∼15 000 person-years of follow-up. Rates of thromboembolism on warfarin were lower than rates observed in patients off warfarin: annual unadjusted rates of thromboembolism on warfarin were 1.5% in women and 1.2% in men. After multivariable adjustment for other risk factors for stroke, warfarin therapy continued to be associated with a significant reduction in the rate of thromboembolism, with an adjusted RR of 0.4 (95% CI, 0.3 to 0.5) in women and 0.6 (95% CI, 0.5 to 0.8) in men. In multivariable models including patients both on and off warfarin therapy, the reduction in rates of thromboembolism with warfarin was larger in women than in men (P=0.01 for the interaction of sex and warfarin).

**Rates of Major Hemorrhage on Warfarin Therapy**

On warfarin, women had similar rates of all major hemorrhage compared with men (1.0% versus 1.1%; adjusted RR, 0.8; 95% CI, 0.6 to 1.1). Women were less likely than men to develop intracranial hemorrhage while on warfarin (0.36% versus 0.55%; adjusted RR, 0.5; 95% CI, 0.3 to 0.9). In multivariable models assessing predictors of intracranial hemorrhage that included patients both on and off warfarin therapy, warfarin therapy was associated with an increased risk for intracranial hemorrhage (adjusted RR, 1.6; 95% CI, 1.1 to 2.4), but women were not at greater risk for developing intracranial hemorrhage.
with warfarin therapy than were men ($P=0.10$ for the interaction term between sex and warfarin use).

**Discussion**

In this large cohort of patients with atrial fibrillation, women had higher rates of ischemic stroke and peripheral embolism while not taking warfarin than did men, even after adjustment for established clinical risk factors for stroke. Higher rates of thromboembolism among women were observed at both younger and older ages and across all stroke risk factor categories. The 30-day mortality rate following an ischemic stroke did not differ by sex, indicating that the increased risk of stroke faced by women was not due to the occurrence of less severe strokes.15

Warfarin appears to be at least as effective for women in reducing the risk of thromboembolism, if not more so, than in men. This observation in our cohort was also reported in the pooled analyses of 5 randomized trials of warfarin for atrial fibrillation.2 Warfarin therapy did not pose a greater risk of major hemorrhagic complications in women. This was particularly true for the most important hemorrhagic complication, namely intracranial hemorrhage.

Some studies have shown that women, especially older women, are less likely to receive warfarin for atrial fibrillation.7,16,17 Our findings indicate that women with atrial fibrillation face a higher absolute risk for thromboembolism independently of other risk factors and should gain more from anticoagulant therapy.

Available risk stratification schemes differ on whether female sex is a risk factor for atrial fibrillation-related thromboembolism (Table 3). We found that women had consistently higher rates of thromboembolism across all stroke risk factor strata and after multivariable adjustment. Our cohort analysis offers several advantages over prior studies. We had substantially greater numbers of person-years of follow-up and outcome events, providing a more powerful assessment. Our cohort is also more contemporary and based in a usual clinical practice setting, potentially yielding more generalizability. In comparison, the AFI and SPAF risk schemes were based on participants in randomized trials completed 10 to 15 years ago.2,3 In contrast to the SPAF analysis, we did not find a significant interaction between patient sex and age $>75$ years. Another advantage of the large size of the cohort is that it allowed us to assess whether women faced an increased risk of warfarin-associated hemorrhage, particularly intracranial hemorrhage. Prior studies did not observe sufficient numbers of intracranial hemorrhages to assess warfarin-sex interactions. This is especially important because the health consequences of intracranial hemorrhage are worse than those resulting from the ischemic strokes we seek to prevent through anticoagulation.18,19 In our ATRIA cohort, warfarin was not more dangerous in women than in men.

The mechanism behind the observed difference in atrial fibrillation-related thromboembolism risk between men and women is unclear. Atrial fibrillation is associated with higher levels of prothrombotic factors, endothelial dysfunction, and markers of platelet activation,20–23 but sex-related differences in these factors have not been well characterized. Interestingly, women with atrial fibrillation may have higher levels of prothrombin fragment F1.2,24 von Willebrand factor,22 and tissue plasminogen activator antigen,25 but studies have not clearly linked these factors to an increased risk of stroke in atrial fibrillation. It also remains to be seen whether differences in left atrial structure and function26,27 contribute to differential thromboembolism risk by sex. Although estrogen replacement therapy has been reported to increase risk of ischemic stroke among postmenopausal women,13 it was not a significant risk factor in our study.

Our study has several limitations. We lacked data on potential differences in left ventricular systolic function and blood pressure control between men and women, factors shown to affect stroke risk.5,28 Although we controlled for the diagnosis of hypertension, we could not adjust for individual patients’ blood pressure levels. It is noteworthy, however, that these factors were also not used in the AFI and CHADS2 risk schemes. We did not have comprehensive information on the use of aspirin in our pharmacy database because many patients used nonprescription forms of aspirin. We addressed this shortcoming in a previous review of the medical charts of 232 randomly sampled patients in our cohort who were not taking warfarin.8 In these nonusers of warfarin, 38% of women and 56% of men were recorded as taking aspirin. Assuming that aspirin reduces thromboembolic event rates by 21%,29 differential use of aspirin between men and women would not materially change our estimate. Thus, it is unlikely that variation in aspirin use between men and women explains their differing rates of thromboembolism. Finally, we note that stroke rates in our cohort were generally lower than those reported in other earlier studies. The reason for these lower rates is not clear but may reflect a somewhat healthier, insured population of patients. Because we lacked information on individual patients’ blood pressure measurements, we were unable to determine whether control of hypertension was better in our cohort than in other populations. In addition, we required that each stroke event be validated by chart review. It is possible that our search strategy

**TABLE 3. Relative Risk of Thromboembolism in Atrial Fibrillation Patients Not Taking Warfarin Comparing Women and Men Across Various Risk Stratification Schemes**

<table>
<thead>
<tr>
<th>Time Off Warfarin, person-years</th>
<th>Women, %</th>
<th>Events, n</th>
<th>Relative Risk, Women vs Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRIA cohort</td>
<td>15 494</td>
<td>44</td>
<td>369 Ischemic strokes, 25 peripheral emboli</td>
</tr>
<tr>
<td>AF2</td>
<td>3432</td>
<td>34</td>
<td>81 Ischemic strokes, 10 peripheral emboli</td>
</tr>
<tr>
<td>SPAF3</td>
<td>3977</td>
<td>28</td>
<td>130 Ischemic strokes</td>
</tr>
<tr>
<td>Framingham cohort†</td>
<td>2844</td>
<td>48</td>
<td>83 Strokes (both ischemic and hemorrhagic)</td>
</tr>
</tbody>
</table>

*Reported as rate ratio.  †Reported as hazard ratio.
missed some stroke events because searching for cerebrovascular diseases using ICD-9 codes may not be highly sensitive.\textsuperscript{29,31}

In conclusion, women have a higher risk than men for atrial fibrillation–related thromboembolism at both younger and older ages that is independent of the presence of other risk factors for stroke. Furthermore, warfarin therapy appears to be at least as effective in women as in men in preventing thromboembolism. Finally, women do not have a higher risk than men for intracranial or other major bleeding events associated with warfarin. On balance, the overall net benefit of warfarin therapy for atrial fibrillation appears to be greater in women compared with men. Our findings indicate that female sex is an important factor supporting the use of anticoagulant therapy in patients with atrial fibrillation.

Acknowledgments
This work was supported by Public Health Services research grant AG15478 from the National Institute on Aging and the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital.

Disclosure
Dr Hylek is currently a principal investigator on 2 industry-sponsored research grants limited to analyses of completed data–sponsored by AstraZeneca. Dr Hylek also served as a panel participant at a symposium source of the other grant, manufactures the brand-name ximelagatran (Exanta). AstraZeneca, the manufacturer of warfarin (Coumadin). AstraZeneca, the source of the other grant, manufactures the brand-name ximelagatran (Exanta). Dr Hylek also served as a panel participant at a symposium sponsored by AstraZeneca.

References
Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study
Margaret C. Fang, Daniel E. Singer, Yuchiao Chang, Elaine M. Hylek, Lori E. Henault, Nancy G. Jensvold and Alan S. Go

Circulation. 2005;112:1687-1691; originally published online September 12, 2005;
doi: 10.1161/CIRCULATIONAHA.105.553438
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/112/12/1687

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/